Cargando…
Cost-Effectiveness Analysis of Psoriasis Treatment Modalities in Malaysia
Background: There is limited evidence detailing the cost-effectiveness of psoriasis treatments in the Asian region. Therefore, this study is aimed to evaluate the cost-effectiveness of 3 psoriasis treatments tailored for moderate to severe psoriasis, namely topical and phototherapy (TP), topical and...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Kerman University of Medical Sciences
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6706977/ https://www.ncbi.nlm.nih.gov/pubmed/31441276 http://dx.doi.org/10.15171/ijhpm.2019.17 |
_version_ | 1783445789331161088 |
---|---|
author | Azizam, Nor Azmaniza Ismail, Aniza Sulong, Saperi Nor, Norazirah Md |
author_facet | Azizam, Nor Azmaniza Ismail, Aniza Sulong, Saperi Nor, Norazirah Md |
author_sort | Azizam, Nor Azmaniza |
collection | PubMed |
description | Background: There is limited evidence detailing the cost-effectiveness of psoriasis treatments in the Asian region. Therefore, this study is aimed to evaluate the cost-effectiveness of 3 psoriasis treatments tailored for moderate to severe psoriasis, namely topical and phototherapy (TP), topical and systemic (TS), and topical and biologic (TB) regimens, respectively. Methods: This has been achieved by the participation of a prospective cohort involving a total of 90 moderate to severe psoriasis patients, which has been conducted at 5 public hospitals in Malaysia. The main outcome measures have been evaluated via cost and effectiveness psoriasis area severity index (PASI)-75 and/or body surface area (BSA) <5 and/or dermatology life quality index (DLQI) ≤5), estimated from the societal perspective over a 6-months duration. All costs are based on 2015’s recorded Malaysian Ringgit (RM) currency. Results: Consequently, TS has been found to be the most cost-effective treatment with the lowest cost/PASI-75/and/or BSA <5 and/or DLQI ≤5, valued at RM9034.56 (US$2582.55). This is followed by TP, which is valued at RM28 080.71 (US$8026.93) and TB, valued at RM54 287.02 (US$15 518.06). Furthermore, one-way sensitivity analysis has highlighted the cost of medication as the most sensitive parameter. Conclusion: Thus, the input from this study is helpful for policy-makers in determining the first line treatment for moderate to severe psoriasis with consideration of the costs and its effectiveness in Malaysia. This will consequently allow hospitals to justify and provide the essential resources for further research and development, as well as the adoption of better treatment options |
format | Online Article Text |
id | pubmed-6706977 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | Kerman University of Medical Sciences |
record_format | MEDLINE/PubMed |
spelling | pubmed-67069772019-08-28 Cost-Effectiveness Analysis of Psoriasis Treatment Modalities in Malaysia Azizam, Nor Azmaniza Ismail, Aniza Sulong, Saperi Nor, Norazirah Md Int J Health Policy Manag Original Article Background: There is limited evidence detailing the cost-effectiveness of psoriasis treatments in the Asian region. Therefore, this study is aimed to evaluate the cost-effectiveness of 3 psoriasis treatments tailored for moderate to severe psoriasis, namely topical and phototherapy (TP), topical and systemic (TS), and topical and biologic (TB) regimens, respectively. Methods: This has been achieved by the participation of a prospective cohort involving a total of 90 moderate to severe psoriasis patients, which has been conducted at 5 public hospitals in Malaysia. The main outcome measures have been evaluated via cost and effectiveness psoriasis area severity index (PASI)-75 and/or body surface area (BSA) <5 and/or dermatology life quality index (DLQI) ≤5), estimated from the societal perspective over a 6-months duration. All costs are based on 2015’s recorded Malaysian Ringgit (RM) currency. Results: Consequently, TS has been found to be the most cost-effective treatment with the lowest cost/PASI-75/and/or BSA <5 and/or DLQI ≤5, valued at RM9034.56 (US$2582.55). This is followed by TP, which is valued at RM28 080.71 (US$8026.93) and TB, valued at RM54 287.02 (US$15 518.06). Furthermore, one-way sensitivity analysis has highlighted the cost of medication as the most sensitive parameter. Conclusion: Thus, the input from this study is helpful for policy-makers in determining the first line treatment for moderate to severe psoriasis with consideration of the costs and its effectiveness in Malaysia. This will consequently allow hospitals to justify and provide the essential resources for further research and development, as well as the adoption of better treatment options Kerman University of Medical Sciences 2019-04-06 /pmc/articles/PMC6706977/ /pubmed/31441276 http://dx.doi.org/10.15171/ijhpm.2019.17 Text en © 2019 The Author(s); Published by Kerman University of Medical Sciences This is an open-access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Original Article Azizam, Nor Azmaniza Ismail, Aniza Sulong, Saperi Nor, Norazirah Md Cost-Effectiveness Analysis of Psoriasis Treatment Modalities in Malaysia |
title | Cost-Effectiveness Analysis of Psoriasis Treatment Modalities in Malaysia |
title_full | Cost-Effectiveness Analysis of Psoriasis Treatment Modalities in Malaysia |
title_fullStr | Cost-Effectiveness Analysis of Psoriasis Treatment Modalities in Malaysia |
title_full_unstemmed | Cost-Effectiveness Analysis of Psoriasis Treatment Modalities in Malaysia |
title_short | Cost-Effectiveness Analysis of Psoriasis Treatment Modalities in Malaysia |
title_sort | cost-effectiveness analysis of psoriasis treatment modalities in malaysia |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6706977/ https://www.ncbi.nlm.nih.gov/pubmed/31441276 http://dx.doi.org/10.15171/ijhpm.2019.17 |
work_keys_str_mv | AT azizamnorazmaniza costeffectivenessanalysisofpsoriasistreatmentmodalitiesinmalaysia AT ismailaniza costeffectivenessanalysisofpsoriasistreatmentmodalitiesinmalaysia AT sulongsaperi costeffectivenessanalysisofpsoriasistreatmentmodalitiesinmalaysia AT nornorazirahmd costeffectivenessanalysisofpsoriasistreatmentmodalitiesinmalaysia |